Lantheus (NASDAQ:LNTH) Stock Rating Reaffirmed as “Neutral” by Mizuho

Lantheus (NASDAQ:LNTH)‘s stock had its “neutral” rating reissued by analysts at Mizuho in a research report issued on Tuesday, Benzinga reports. They currently have a $109.00 target price on the medical equipment provider’s stock, down from their previous target price of $115.00. Mizuho’s target price would suggest a potential upside of 8.88% from the stock’s current price.

A number of other brokerages also recently issued reports on LNTH. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and lowered their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Finally, CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Three research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $107.44.

Lantheus Stock Down 0.0%

Shares of NASDAQ:LNTH opened at $100.11 on Tuesday. The company has a market cap of $6.53 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06. Lantheus has a 12 month low of $50.15 and a 12 month high of $111.86. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $100.47 and a 200 day moving average price of $97.20.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.57 earnings per share. As a group, equities research analysts predict that Lantheus will post 4.54 earnings per share for the current year.

Institutional Trading of Lantheus

A number of large investors have recently made changes to their positions in LNTH. Western Wealth Management LLC purchased a new stake in Lantheus in the 1st quarter valued at about $25,000. Bessemer Group Inc. grew its stake in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares in the last quarter. Allworth Financial LP bought a new position in Lantheus in the 2nd quarter worth about $49,000. Farther Finance Advisors LLC increased its position in shares of Lantheus by 122.9% during the third quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 306 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Lantheus by 33.0% during the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 146 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.